Bing

SEARCH HISTORY

Questcor Pharmaceuticals (QCOR) is seeing its price rise on above-normal volume today, as four million shares, 2.7 times the stock's average daily volume, have moved. The stock price is $56.00, a 11.5% increase. The stock is trading 18.7% above its …
Fox Business · 7/9/2012
How handsome? The best-performing stock in the broad Standard & Poor's 1500 index in 2011 that is still in the index was Questcor Pharmaceuticals (QCOR). The biotech company, which is working on treatments for multiple sclerosis, among other things ...
USA Today · ByMatt Krantz · 10/16/2012
As a result of the merger, shareholders are anticipated to receive $30 in cash and .897 shares of Mallinckrodt for each share of Questcor stock. On February 27, 2014 and March 14, 2014 respectively, research analyst firm Citron Research published two ...
The Business Journal · 4/29/2014
Tom Garrity: A great stock I recommended to my subscribers in 2010 was Questcor Pharmaceuticals (QCOR). Questcor manufactures an injectable drug called Acthar, which targets Multiple Sclerosis (MS) flares, Nephrotic Syndrome (NS) and Infantile …
Cabot Investing Advice · 2/18/2013
Valeant will pay $44 a share for Medicis, a 39% premium to the stock’s Friday closing price. Medicis shares surged 38% to $43.47 premarket; Valeant shares were also higher, trading up 9.8% to $56.29. Questcor Pharmaceuticals Inc. (QCOR) said it has ...
The Wall Street Journal · ByMia Lamar · 9/4/2012
He manages the Hussman Strategic Growth Fund and the Hussman Strategic Total Return Fund, which invests ... Pharmaceuticals (QCOR), which develops prescription drugs for central nervous system disorders. The company’s stock has been up 70% …
Guru Focus · 11/13/2014
Questcor (QCOR): After such a big run, I'm cautious, said Cramer. Southern Copper (SCCO): I don't think copper is that good, said Cramer, and I don't want to own this stock. Getty Images SunPower (SPWR): If I wanted to own a solar stock it would be First ...
CNBC · ByLee Brodie · 8/28/2013
Questcor Pharmaceuticals ($QCOR) got a big boost yesterday after an Oppenheimer analyst raised his price target on the stock, citing Medicaid rebate changes that could boost sales of its Acthar drug by almost $100 million next year. Today, Aetna all but ...
FiercePharma · ByTracy Staton · 9/19/2012
We continue to believe that if QCOR at least holds revenues and earnings constant with 2Q 2012, the stock is undervalued, and if the company delivers quarterly results in line with 3Q 2012 expectations - growth - the stock will move higher. Traditionally ...
Yahoo New Zealand · 10/22/2012
Something in the area of health care, a Questcor (QCOR). These are companies ... A smaller company, but you can see the stock hitting an all-time high towards the end of the year in 2011. Also read: 4 Growth Names Ready to Pop in 2012 Kate Stalter ...
The Money Show · 1/2/2012